ArticleStem cells translational medicine2016
First Proposal of Minimum Information About a Cellular Assay for Regenerative Medicine.
Article in Stem cells translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- A Data Driven Review of In Vitro Electrical and Mechanical Stimulation for Post-Acute Phase Wound Healing.Advanced healthcare materials · 2026Review
- Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review.Medical sciences (Basel, Switzerland) · 2026Review
- A template wizard for the cocreation of machine-readable data-reporting to harmonize the evaluation of (nano)materials.Nature protocols · 2024Review
- Article
- Effect of Bergenin on Human Gingival Fibroblast Response on Zirconia Implant Surfaces: An In Vitro Study.Journal of functional biomaterials · 2023Article
- Tolerogenic dendritic cell reporting: Has a minimum information model made a difference?PeerJ · 2023Article
- Towards an Open-Source Platform to Harmonize and Share Research Results from COVID-19 Interventional and Observational Studies.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2023Article
- Human pluripotent stem cell registry: Operations, role and current directions.Cell proliferation · 2022Review
- A Web-based Platform to Share Harmonized Results from COVID-19 Clinical Studies.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2022Article
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).European journal of immunology · 2021Review
- ReMeDy: a platform for integrating and sharing published stem cell research data with a focus on iPSC trials.Database : the journal of biological databases and curation · 2021Article
- Integrated Collection of Stem Cell Bank Data, a Data Portal for Standardized Stem Cell Information.Stem cell reports · 2021Article
- Human Cell Atlas and cell-type authentication for regenerative medicine.Experimental & molecular medicine · 2020Review
- Studying Abnormal Chromosomal Diseases Using Patient-Derived Induced Pluripotent Stem Cells.Frontiers in cellular neuroscience · 2020Article
- Informatics Approaches for Harmonized Intelligent Integration of Stem Cell Research.Stem cells and cloning : advances and applications · 2020Review
- OSCI: standardized stem cell ontology representation and use cases for stem cell investigation.BMC bioinformatics · 2019Article
- Report of the International Stem Cell Banking Initiative Workshop Activity: Current Hurdles and Progress in Seed-Stock Banking of Human Pluripotent Stem Cells.Stem cells translational medicine · 2017Article
- Implications for a Stem Cell Regenerative Medicine Based Approach to Human Intervertebral Disk Degeneration.Frontiers in cell and developmental biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
Abstract
: Advances in stem cell research have triggered scores of studies in regenerative medicine in a large number of institutions and companies around the world. However, reproducibility and data exchange among laboratories or cell banks are constrained by the lack of a standardized format for experiments. To enhance information flow in stem cell and derivative cell research, here we propose a minimum information standard to describe cellular assay data to facilitate practical regenerative medicine. Based on the existing Minimum Information About a Cellular Assay, we developed Minimum Information About a Cellular Assay for Regenerative Medicine (MIACARM), which allows for the description of advanced cellular experiments with defined taxonomy of human cell types. By using controlled terms, such as ontologies, MIACARM will provide a platform for cellular assay data exchange among cell banks or registries that have been established at more than 20 sites in the world. SIGNIFICANCE: Currently, there are more than 20 human cell information storage sites around the world. However, reproducibility and data exchange among different laboratories or cell information providers are usually inadequate or nonexistent because of the lack of a standardized format for experiments. This study, which is the fruit of collaborative work by scientists at stem cell banks and cellular information registries worldwide, including those in the U.S., the U.K., Europe, and Japan, proposes new minimum information guidelines, Minimum Information About a Cellular Assay for Regenerative Medicine (MIACARM), for cellular assay data deposition. MIACARM is intended to promote data exchange and facilitation of practical regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.